198 related articles for article (PubMed ID: 31146605)
21. FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3β/β- catenin signaling cascade via FGFR4 activation.
Zhao H; Lv F; Liang G; Huang X; Wu G; Zhang W; Yu L; Shi L; Teng Y
Oncotarget; 2016 Mar; 7(12):13575-86. PubMed ID: 26498355
[TBL] [Abstract][Full Text] [Related]
22. BLU-554, A selective inhibitor of FGFR4, exhibits anti-tumour activity against gastric cancer in vitro.
Zhang X; Zhang X; Han R; Wang Z; Yang Q; Huang Y; Yan Y
Biochem Biophys Res Commun; 2022 Mar; 595():22-27. PubMed ID: 35093636
[TBL] [Abstract][Full Text] [Related]
23. Src is essential for the endosomal delivery of the FGFR4 signaling complex in hepatocellular carcinoma.
Shin JY; Ahn SM
J Transl Med; 2021 Apr; 19(1):138. PubMed ID: 33794926
[TBL] [Abstract][Full Text] [Related]
24. FGFR4: A promising therapeutic target for breast cancer and other solid tumors.
Levine KM; Ding K; Chen L; Oesterreich S
Pharmacol Ther; 2020 Oct; 214():107590. PubMed ID: 32492514
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis and biological evaluation of quinazoline derivatives as potent and selective FGFR4 inhibitors.
Pan C; Nie W; Wang J; Du J; Pan Z; Gao J; Lu Y; Che J; Zhu H; Dai H; Chen B; He Q; Dong X
Eur J Med Chem; 2021 Dec; 225():113794. PubMed ID: 34488024
[TBL] [Abstract][Full Text] [Related]
26. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models.
Desnoyers LR; Pai R; Ferrando RE; Hötzel K; Le T; Ross J; Carano R; D'Souza A; Qing J; Mohtashemi I; Ashkenazi A; French DM
Oncogene; 2008 Jan; 27(1):85-97. PubMed ID: 17599042
[TBL] [Abstract][Full Text] [Related]
27. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.
Gao L; Wang X; Tang Y; Huang S; Hu CA; Teng Y
J Exp Clin Cancer Res; 2017 Jan; 36(1):8. PubMed ID: 28069043
[TBL] [Abstract][Full Text] [Related]
28. Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.
Hatlen MA; Schmidt-Kittler O; Sherwin CA; Rozsahegyi E; Rubin N; Sheets MP; Kim JL; Miduturu C; Bifulco N; Brooijmans N; Shi H; Guzi T; Boral A; Lengauer C; Dorsch M; Kim RD; Kang YK; Wolf BB; Hoeflich KP
Cancer Discov; 2019 Dec; 9(12):1686-1695. PubMed ID: 31575540
[TBL] [Abstract][Full Text] [Related]
29. Anti-cancer effects of 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives on hepatocellular carcinoma harboring FGFR4 activation.
Nam Y; Shin I; Kim Y; Ryu S; Kim N; Ju E; Sim T
Neoplasia; 2022 Jan; 24(1):34-49. PubMed ID: 34864570
[TBL] [Abstract][Full Text] [Related]
30. Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models.
French DM; Lin BC; Wang M; Adams C; Shek T; Hötzel K; Bolon B; Ferrando R; Blackmore C; Schroeder K; Rodriguez LA; Hristopoulos M; Venook R; Ashkenazi A; Desnoyers LR
PLoS One; 2012; 7(5):e36713. PubMed ID: 22615798
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis, and anticancer evaluation of arylurea derivatives as potent and selective type II irreversible covalent FGFR4 inhibitors.
Wang M; Lan L; Wang YW; Zhang JY; Shi L; Sun LP
Bioorg Med Chem; 2023 May; 87():117298. PubMed ID: 37196426
[TBL] [Abstract][Full Text] [Related]
32. Discovery of novel FGFR4 inhibitors through a build-up fragment strategy.
Kim J; Im CG; Oh K; Lee JM; Al-Rubaye F; Min KH
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2343350. PubMed ID: 38655602
[TBL] [Abstract][Full Text] [Related]
33. EGFR Inhibition Overcomes Resistance to FGFR4 Inhibition and Potentiates FGFR4 Inhibitor Therapy in Hepatocellular Carcinoma.
Shen B; Shi JP; Zhu ZX; He ZD; Liu SY; Shi W; Zhang YX; Ying HY; Wang J; Xu RF; Fang F; Chang HX; Chen Z; Zhang NN
Mol Cancer Ther; 2023 Dec; 22(12):1479-1492. PubMed ID: 37710057
[TBL] [Abstract][Full Text] [Related]
34. Developing FGFR4 inhibitors as potential anti-cancer agents via in silico design, supported by in vitro and cell-based testing.
Ho HK; Németh G; Ng YR; Pang E; Szántai-Kis C; Zsákai L; Breza N; Greff Z; Horváth Z; Pató J; Szabadkai I; Szokol B; Baska F; Őrfî L; Ullrich A; Kéri G; Chua BT
Curr Med Chem; 2013; 20(10):1203-17. PubMed ID: 23409720
[TBL] [Abstract][Full Text] [Related]
35. Targeting the FGF19-FGFR4 pathway for cholestatic, metabolic, and cancerous diseases.
Li X; Lu W; Kharitonenkov A; Luo Y
J Intern Med; 2024 Mar; 295(3):292-312. PubMed ID: 38212977
[TBL] [Abstract][Full Text] [Related]
36. Fibroblast growth factor receptor 4 promotes progression and correlates to poor prognosis in cholangiocarcinoma.
Xu YF; Yang XQ; Lu XF; Guo S; Liu Y; Iqbal M; Ning SL; Yang H; Suo N; Chen YX
Biochem Biophys Res Commun; 2014 Mar; 446(1):54-60. PubMed ID: 24565842
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis, and biological evaluation of selective covalent inhibitors of FGFR4.
Chen X; Li H; Lin Q; Dai S; Qu L; Guo M; Zhang L; Liao J; Wei H; Xu G; Jiang L; Chen Y
Eur J Med Chem; 2024 Mar; 268():116281. PubMed ID: 38432058
[TBL] [Abstract][Full Text] [Related]
38. Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer.
Turkington RC; Longley DB; Allen WL; Stevenson L; McLaughlin K; Dunne PD; Blayney JK; Salto-Tellez M; Van Schaeybroeck S; Johnston PG
Cell Death Dis; 2014 Feb; 5(2):e1046. PubMed ID: 24503538
[TBL] [Abstract][Full Text] [Related]
39. Paralog-Specific Kinase Inhibition of FGFR4: Adding to the Arsenal of Anti-FGFR Agents.
Packer LM; Pollock PM
Cancer Discov; 2015 Apr; 5(4):355-7. PubMed ID: 25847957
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling.
Pai R; Dunlap D; Qing J; Mohtashemi I; Hotzel K; French DM
Cancer Res; 2008 Jul; 68(13):5086-95. PubMed ID: 18593907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
